Cone Health Center for Infectious Disease Opens International HIV Prevention Study
If successful, members of our community may more easily avoid HIV infections.
Men who have sex with men and transgender women who have sex with men can now take part in an international trial designed to prevent the spread of human immunodeficiency virus (HIV). Regional Center for Infectious Disease (RCID), a member of Cone Health Medical Group, is a site for the TRIUMPH trial. The trial is offered through the worldwide HIV Prevention Trials Network. RCID and the University of North Carolina-Chapel Hill are the only sites in North Carolina offering this study.
“It is really exciting that we can bring this groundbreaking research to people in our community,” says Kees Van Dam, MD, director of research, RCID. “Along with expanding HIV testing and treatment, finding a simple, reliable medication to protect people who don’t have HIV, but are at risk of getting it will be critical to ending the epidemic.”
The TRIUMPH study will determine whether an injectable drug – usually given every couple of months – can safely protect men who have sex with men and transgender women who have sex with men from acquiring HIV as well as the current FDA-approved pill, Truvada. If found to be safe and effective, the injectable drug may be easier for people than having to remember to take a daily pill. The study is funded by the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and ViiV Healthcare.
The trial is taking place in eight countries, including the United States. The Greensboro-High Point area is ranked 20th among major metropolitan areas in the United States in the number of new HIV infections per capita. “Because we are living at one of the epicenters of HIV transmission,” says Van Dam, “we feel that Greensboro is an ideal place to push the frontiers of HIV prevention research.”
People interested in learning more about the TRIUMPH study and about becoming a participant can:
After an in-person screening, study participants will be compensated for their time.